Marshall Wace’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.34M | Buy |
2,353,122
+2,267,583
| +2,651% | +$5.15M | 0.01% | 1018 |
|
|
2025
Q1 | $54.7K | Buy |
+85,539
| New | +$54.7K | ﹤0.01% | 2393 |
|
|
2024
Q2 | – | Sell |
-52,289
| Closed | -$114K | – | 2363 |
|
|
2024
Q1 | $114K | Sell |
52,289
-310,987
| -86% | -$678K | ﹤0.01% | 2018 |
|
|
2023
Q4 | $563K | Sell |
363,276
-14,317
| -4% | -$22.2K | ﹤0.01% | 1399 |
|
|
2023
Q3 | $487K | Sell |
377,593
-296,908
| -44% | -$383K | ﹤0.01% | 1455 |
|
|
2023
Q2 | $1.16M | Sell |
674,501
-55,437
| -8% | -$95.4K | ﹤0.01% | 1321 |
|
|
2023
Q1 | $1.1M | Buy |
+729,938
| New | +$1.1M | ﹤0.01% | 1382 |
|
|
2022
Q4 | – | Sell |
-40,021
| Closed | -$58K | – | 2397 |
|
|
2022
Q3 | $58K | Sell |
40,021
-24,123
| -38% | -$35K | ﹤0.01% | 2455 |
|
|
2022
Q2 | $118K | Buy |
64,144
+48,878
| +320% | +$89.9K | ﹤0.01% | 2534 |
|
|
2022
Q1 | $40K | Buy |
+15,266
| New | +$40K | ﹤0.01% | 2519 |
|
|
2020
Q2 | – | Sell |
-117,393
| Closed | -$900K | – | 1585 |
|
|
2020
Q1 | $900K | Sell |
117,393
-284,033
| -71% | -$2.18M | 0.01% | 818 |
|
|
2019
Q4 | $3.34M | Buy |
401,426
+393,401
| +4,902% | +$3.27M | 0.02% | 625 |
|
|
2019
Q3 | $59K | Buy |
+8,025
| New | +$59K | ﹤0.01% | 1425 |
|
|
2019
Q1 | – | Sell |
-51,876
| Closed | -$783K | – | 1760 |
|
|
2018
Q4 | $783K | Sell |
51,876
-28,532
| -35% | -$431K | 0.01% | 972 |
|
|
2018
Q3 | $1.49M | Buy |
+80,408
| New | +$1.49M | 0.01% | 734 |
|
|
2018
Q2 | – | Sell |
-12,100
| Closed | -$344K | – | 724 |
|
|
2018
Q1 | $344K | Buy |
+12,100
| New | +$344K | 0.01% | 440 |
|